| Filed On | Filing |
|---|---|
| 07 Oct 2026 | SCHEDULE 13G/A |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform |
| 25 Aug 2026 | 8-K: Regulation FD Disclosure |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 02 Jul 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 15 Jun 2026 |
Form 4: Holmes Edward W, Director
Granted 15,000 Stock option (right to buy) |
| 15 Jun 2026 |
Form 4: Farrell Peter C, Director
Granted 15,000 Stock option (right to buy) |
| 15 Jun 2026 |
Form 4: Barlow James F, Director
Granted 15,000 Stock option (right to buy) |
| 15 Jun 2026 |
Form 4: Markels John, Director
Granted 15,000 Stock option (right to buy) |
| 15 Jun 2026 |
Form 4: Slaoui Moncef, Director
Granted 15,000 Stock option (right to buy) |
| 15 Jun 2026 |
Form 4: Marquet Magda, Director
Granted 15,000 Stock option (right to buy) |
| 15 Jun 2026 |
Form 4: Marantz Jing L., Director
Granted 15,000 Stock option (right to buy) |
| 05 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 07 May 2026 |
Form 4: Mulroy Dennis, Chief Financial Officer
Granted 100,000 Employee Stock Option (right to buy) |
| 07 May 2026 |
Form 3: Mulroy Dennis, Chief Financial Officer
No securities owned |
| 07 May 2026 | 10-Q |
| 07 May 2026 | SCHEDULE 13G/A |
| 07 May 2026 | 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more |
| 24 Apr 2026 |
Proxy statement: annual meeting on June 5, 2026
say-on-pay vote |
Loading...
